Phase 1b Window of Opportunity Study of Peri-prostatic Neurolysis in High-risk Localized Prostate Cancer

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The purpose of this research study is to assess whether inhibiting nerve activity to the prostate delays progression of disease in men with high-risk clinical features for prostate cancer. Prostate cancer has been shown to invade nerves, a mechanism that is thought to be involved in prostate cancer spread in men with high-risk cancer. When nerve activity to the prostate is blocked in mice with prostate cancer, prostate cancer growth and spread are inhibited. In a previous study we showed that doing so in humans was safe and may have anticancer therapeutic effect. In this study we will test whether one versus two injections of nerve blocking agent is more effective at reducing nerves in the prostate and whether it will slow/stop spread of prostate cancer after treatment.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:

• High risk prostate cancer as defined by NCCN criteria Desires surgical disease treatment (radical prostatectomy) Surgical candidate (for radical prostatectomy)

• ≤cT3a on MRI No seminal vesicle, lymph node, or metastatic disease on PSMA PET No prior prostate cancer treatment (including androgen deprivation therapy, radiation therapy, focal therapy, cryo therapy)

Locations
United States
Texas
University of Texas Southwestern Medical Center
RECRUITING
Dallas
Time Frame
Start Date: 2025-08-15
Estimated Completion Date: 2028-08
Participants
Target number of participants: 21
Treatments
Experimental: Single injection neurolysis
Single injection of ethanol for periprostatic neurolysis
Experimental: Two injection neurolysis
Two temporally separated periprostatic ethanol injections
No_intervention: No injection control
Related Therapeutic Areas
Sponsors
Collaborators: Urology Care Foundation, American Urological Association
Leads: University of Texas Southwestern Medical Center

This content was sourced from clinicaltrials.gov